InvestorsHub Logo
Followers 94
Posts 11325
Boards Moderated 0
Alias Born 11/02/2003

Re: None

Thursday, 08/11/2022 8:36:40 AM

Thursday, August 11, 2022 8:36:40 AM

Post# of 352
NEWS -- Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights



  • Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational study in HR+/HER2- breast cancer
  • Achieved success criteria for efficacy in Stage 1 of the GOBLET trial's pancreatic cancer cohort with partial responses in all phase 1b patients
  • Clinical biomarker data show pelareorep remodeling tumor microenvironments to improve prognosis and decrease the risk of recurrence in HR+/HER2- breast cancer patients
  • $33.7 million in cash and cash equivalents provides projected runway into the second half of 2023 and through key clinical readouts in breast and pancreatic cancer
  • Management hosting conference call and webcast today at 8:30 a.m. ET
To see full Press Release follow link here:

https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-second-quarter-2022-financial-results-and-recent-operational-highlights-301604104.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCY News